Skip to main content

Zika Virus

3
Pipeline Programs
7
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
3100%
+ 10 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
3 programs
1
TetraVax-DV-TV003Phase 11 trial
RT-PCRN/A1 trial
Single dose of rZIKV/D4Δ30-713PHASE_11 trial
Active Trials
NCT03106714Completed260Est. Jun 2020
NCT03611946Completed56Est. Mar 2022
NCT06805487Completed27Est. Sep 2025
Valneva
ValnevaAustria - Vienna
1 program
1
VLA1601Phase 11 trial
Active Trials
NCT03425149Completed67Est. Nov 2018
Emergent BioSolutions
1 program
1
VLA1601Phase 1
Moderna
ModernaCAMBRIDGE, MA
3 programs
mRNA-1325PHASE_1RNA Therapeutic1 trial
mRNA-1893PHASE_1RNA Therapeutic1 trial
mRNA-1893PHASE_2RNA Therapeutic1 trial
Active Trials
NCT03014089Completed90Est. Jul 2019
NCT04064905Completed120Est. Mar 2021
NCT04917861Completed808Est. Jul 2024
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, NicaraguaN/A1 trial
Neurodevelopmental assessmentsN/A1 trial
Active Trials
NCT04182685Completed410Est. Dec 2020
NCT04398901Enrolling By Invitation204Est. Dec 2025
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
ZIKAlliance Natural History StudyN/A1 trial
ZIKAlliance Pregnant Women CohortN/A1 trial
Active Trials
NCT03204409Withdrawn0Est. Sep 2021
NCT03188731Completed3,852Est. Sep 2021
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
ZIKAlliance Pregnant Women CohortN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
ModernamRNA-1893
Allergy TherapeuticsTetraVax-DV-TV003
ModernamRNA-1893
Allergy TherapeuticsSingle dose of rZIKV/D4Δ30-713
ValnevaVLA1601
ModernamRNA-1325
Human BioSciencesNeurodevelopmental assessments
Human BioSciencesEvaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua
Heidelberg PharmaZIKAlliance Natural History Study
Allergy TherapeuticsRT-PCR
Heidelberg PharmaZIKAlliance Pregnant Women Cohort

Clinical Trials (11)

Total enrollment: 5,894 patients across 11 trials

NCT04917861ModernamRNA-1893

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

Start: Jun 2021Est. completion: Jul 2024808 patients
Phase 2Completed
NCT06805487Allergy TherapeuticsTetraVax-DV-TV003

Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge

Start: Sep 2024Est. completion: Sep 202527 patients
Phase 1Completed
NCT04064905ModernamRNA-1893

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

Start: Jul 2019Est. completion: Mar 2021120 patients
Phase 1Completed
NCT03611946Allergy TherapeuticsSingle dose of rZIKV/D4Δ30-713

Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults

Start: Jul 2018Est. completion: Mar 202256 patients
Phase 1Completed
NCT03425149ValnevaVLA1601

Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults

Start: Feb 2018Est. completion: Nov 201867 patients
Phase 1Completed
NCT03014089ModernamRNA-1325

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

Start: Dec 2016Est. completion: Jul 201990 patients
Phase 1Completed
NCT04398901Human BioSciencesNeurodevelopmental assessments

Neurodevelopmental Outcomes in ZIKV-Exposed Children

Start: Nov 2020Est. completion: Dec 2025204 patients
N/AEnrolling By Invitation
NCT04182685Human BioSciencesEvaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua

Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua

Start: Oct 2019Est. completion: Dec 2020410 patients
N/ACompleted
NCT03204409Heidelberg PharmaZIKAlliance Natural History Study

ZIKAlliance Natural History Study

Start: Apr 2018Est. completion: Sep 20210
N/AWithdrawn
NCT03106714Allergy TherapeuticsRT-PCR

Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil

Start: Jul 2017Est. completion: Jun 2020260 patients
N/ACompleted
NCT03188731Heidelberg PharmaZIKAlliance Pregnant Women Cohort

ZIKAlliance Pregnant Women Cohort

Start: May 2017Est. completion: Sep 20213,852 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.